BTK and chronic myelogenous leukemia, BCR-ABL1 positive: Of note, other tyrosine kinase inhibitors such BTK and BCR-ABL inhibitors have been clinically used to treat B-cell malignancies and chronic myeloid leukemia by inducing efficient cancer cell death44,45.